We are live on ! Find out more
ENGN icon

enGene Therapeutics
ENGN

61 hedge funds and large institutions have $382M invested in enGene Therapeutics in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

7% more funds holding

Funds holding: 57 → 61 (+4)

3.82% less ownership

Funds ownership: 87.63% → 83.81% (-3.8%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

28% less capital invested

Capital invested by funds: $530M → $382M (-$148M)

Holders
61
Holders Change
+4
Holders Change %
+7.02%
% of All Funds
0.75%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
12
Increased
22
Reduced
14
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SL
Siren LLC
Connecticut
+$17.1M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$10.2M
3
VPC
Vestal Point Capital
New York
+$9.88M
4
BOCH
Blue Owl Capital Holdings
New York
+$9.4M
5
KCM
Kennedy Capital Management
Missouri
+$3.11M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$36.1M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$17.1M
3
EAM
Eventide Asset Management
Massachusetts
-$8.58M
4
B
Braidwell
Connecticut
-$6M
5
Morgan Stanley
Morgan Stanley
New York
-$5.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
FIS
1
FCPM III Services
Netherlands
$65.6M – – –
PA
2
Perceptive Advisors
New York
$39.7M -$370K -41,570 -0.7%
SL
3
Siren LLC
Connecticut
$35.8M +$17.1M +1,916,895 +57%
VA
4
VR Adviser
New York
$32.5M – – –
BOCH
5
Blue Owl Capital Holdings
New York
$30.1M +$9.4M +1,055,416 +31%
DTC
6
Deep Track Capital
Connecticut
$29.8M – – –
B
7
Braidwell
Connecticut
$16.7M -$6M -674,449 -22%
NI
8
Nextech Invest
Switzerland
$15.8M +$1.78M +200,000 +9%
VPC
9
Vestal Point Capital
New York
$14.7M +$9.88M +1,110,000 +105%
MB
10
MPM BioImpact
Massachusetts
$12.6M +$39.8K +4,475 +0.2%
KCM
11
Kynam Capital Management
New Jersey
$9.24M -$1.21M -136,055 -9%
Franklin Resources
12
Franklin Resources
California
$8.96M -$650K -73,007 -5%
PCH
13
Polar Capital Holdings
United Kingdom
$8.34M +$722K +81,089 +7%
Balyasny Asset Management
14
Balyasny Asset Management
Illinois
$7.82M +$10.2M +1,148,997 New
Millennium Management
15
Millennium Management
New York
$6.54M -$4.81M -539,839 -36%
OFM
16
Omega Fund Management
Massachusetts
$5.97M – – –
SOCM
17
SR One Capital Management
Pennsylvania
$5.09M – – –
AAA
18
Affinity Asset Advisors
New York
$4.16M -$294K -33,000 -5%
EP
19
Eversept Partners
New York
$3.48M +$487K +54,708 +12%
KCM
20
Kennedy Capital Management
Missouri
$2.9M +$3.11M +349,016 +455%
PFM
21
Privium Fund Management
Netherlands
$2.4M – – –
Marshall Wace
22
Marshall Wace
United Kingdom
$2.34M – – –
MIM
23
Monashee Investment Management
Massachusetts
$2.18M +$223K +25,000 +8%
WP
24
Woodline Partners
California
$1.7M – – –
BC
25
Birchview Capital
Vermont
$1.7M +$2.23M +250,000 New
1
2 3

ENGN Hedge Fund Activity: Q1 2026 in Review

61 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q1 2026, worth a combined $382M — down 28% from $530M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ENGN positions and 8 closed out — a net gain of 4 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was Siren LLC, adding an estimated $17.1M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $36.1M sold.

  • 61 institutional investors held enGene Therapeutics (ENGN) as of Q1 2026, up from 57 in Q4 2025.
  • Funds reported $382M of enGene Therapeutics stock for Q1 2026, down 28% quarter-over-quarter.
  • 12 funds opened new enGene Therapeutics positions in Q1 2026 and 8 closed out, a net change of +4 holders.
  • The largest enGene Therapeutics buyer in Q1 2026 was Siren LLC, an estimated $17.1M added.
  • The largest enGene Therapeutics seller in Q1 2026 was Cormorant Asset Management, an estimated $36.1M sold.

Based on aggregated 13F filings for Q1 2026.